Rowe Christopher C, Villemagne Victor L
Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia.
J Nucl Med Technol. 2013 Mar;41(1):11-8. doi: 10.2967/jnumed.110.076315. Epub 2013 Feb 8.
Imaging of brain β-amyloid plaques with (18)F-labeled tracers for PET will likely be available in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly growing prevalence of AD as the population ages, and the increasing emphasis on early diagnosis and treatment, brain amyloid imaging is set to become a widely performed investigation. All physicians reading PET scans will need to know the complex relationship between amyloid and cognitive decline, how to best acquire and display images for detection of amyloid, and how to recognize the patterns of tracer binding in AD and other causes of dementia. This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation.
使用（18）F标记的示踪剂进行正电子发射断层扫描（PET）对脑β淀粉样蛋白斑块成像，可能会在临床实践中用于辅助阿尔茨海默病（AD）的诊断。随着人口老龄化，AD的患病率迅速上升，且对早期诊断和治疗的重视程度不断提高，脑淀粉样蛋白成像将成为一项广泛开展的检查。所有阅读PET扫描结果的医生都需要了解淀粉样蛋白与认知衰退之间的复杂关系，如何以最佳方式获取和显示用于检测淀粉样蛋白的图像，以及如何识别AD和其他痴呆病因中示踪剂结合的模式。本文将为核医学医生提供理解这项新兴检查所需的背景知识，包括其合理应用，并使他们为扫描解读的实践培训做好准备。
